Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Pemetrexed

FDA-approved product (solution, intravenous), marketed as Pemetrexed, Pemfexy, Axtle and 3 more.

Registered studies
50+
Lab records
6
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Pemetrexed
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Adenocarcinoma
  • Cancer
  • Large cell lung carcinoma
  • Lung large cell carcinoma
  • Malignant Mesothelioma
  • Malignant peritoneal mesothelioma
  • Malignant pleural mesothelioma
  • Mesothelioma
  • Neoplasm
  • Non-small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Folic acid analogues
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA35.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli13.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae28.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis48.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • E. coli: measured active in 2 of 6 lab records
Open Pemetrexed in ChEMBL Registered studies below
Show the 6 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Pemetrexed with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

    NCT03976323 · start 2019-06-28

    Registered record
    Registry ID
    NCT03976323
    Conditions
    Carcinoma, Nonsquamous Non-small-cell Lung
    Interventions
    Pembrolizumab; Pemetrexed; Carboplatin; Cisplatin; Olaparib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-06-28
    Completion
    2026-01-29
    Enrolment
    1,003

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Nonsquamous Non-small-cell Lung
    InterventionPembrolizumab; Pemetrexed; Carboplatin; Cisplatin +1 more
    PhasePhase 3
    Registry statusCompleted

  • Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors

    NCT03509012 · start 2018-05-02

    Registered record
    Registry ID
    NCT03509012
    Conditions
    Carcinoma, Squamous Cell of Head and Neck; Carcinoma, Non-Small-Cell Lung; Small Cell Lung Carcinoma
    Interventions
    Durvalumab; Tremelimumab; Cisplatin (dose level 4); Cisplatin (dose level 3); Carboplatin (dose level 1); Carboplatin (dose level 2); Etoposide (dose level 1); Etoposide (dose level 2); Paclitaxel; Pemetrexed; External beam radiation (dose level 1); External beam radiation (dose level 2); External beam radiation (hyperfractionated); Cisplatin (dose level 1); Cisplatin (dose level 2); External beam radiation (standard)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-05-02
    Completion
    2025-01-08
    Enrolment
    105

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Squamous Cell of Head and Neck; Carcinoma, Non-Small-Cell Lung; Small Cell Lung Carcinoma
    InterventionDurvalumab; Tremelimumab; Cisplatin (dose level 4); Cisplatin (dose level 3) +12 more
    PhasePhase 1
    Registry statusCompleted

  • Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) ( KEYVIBE-001)

    NCT02964013 · start 2016-12-13

    Registered record
    Registry ID
    NCT02964013
    Conditions
    Neoplasms
    Interventions
    vibostolimab; pembrolizumab; pemetrexed; carboplatin; pembrolizumab/vibostolimab coformulation; cisplatin; etoposide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-12-13
    Completion
    2024-07-24
    Enrolment
    474

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeoplasms
    Interventionvibostolimab; pembrolizumab; pemetrexed; carboplatin +3 more
    PhasePhase 1
    Registry statusCompleted

  • Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients

    NCT02579564 · start 2016-10

    Registered record
    Registry ID
    NCT02579564
    Conditions
    Malignant Hydrothorax; Non Small Cell Lung Cancer
    Interventions
    Gemcitabine; Vinorelbine; Paclitaxel; Pemetrexed; Oncorine; Endostar; Cisplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2016-10
    Completion
    2018-12
    Enrolment
    134

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalignant Hydrothorax; Non Small Cell Lung Cancer
    InterventionGemcitabine; Vinorelbine; Paclitaxel; Pemetrexed +3 more
    PhasePhase 3
    Registry statusUnknown

  • Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)-China Extension Study

    NCT03850444 · start 2016-08-01

    Registered record
    Registry ID
    NCT03850444
    Conditions
    Non-small Cell Lung Cancer
    Interventions
    pembrolizumab; carboplatin; paclitaxel; pemetrexed
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-08-01
    Completion
    2022-09-08
    Enrolment
    262

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer
    Interventionpembrolizumab; carboplatin; paclitaxel; pemetrexed
    PhasePhase 3
    Registry statusCompleted

  • Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery

    NCT02607423 · start 2015-11-19

    Registered record
    Registry ID
    NCT02607423
    Conditions
    Stage IIIA Non-Small Cell Lung Cancer
    Interventions
    Cisplatin; Computed Tomography; Docetaxel; Fludeoxyglucose F-18; Gemcitabine Hydrochloride; Pemetrexed Disodium; Positron Emission Tomography
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2015-11-19
    Completion
    2017-01-31
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStage IIIA Non-Small Cell Lung Cancer
    InterventionCisplatin; Computed Tomography; Docetaxel; Fludeoxyglucose F-18 +3 more
    PhasePhase 2
    Registry statusWithdrawn

  • Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)

    NCT02542293 · start 2015-11-03

    Registered record
    Registry ID
    NCT02542293
    Conditions
    Non Small Cell Lung Carcinoma NSCLC
    Interventions
    Durvalumab +Tremelimumab; Paclitaxel + carboplatin; Gemcitabine + cisplatin; Gemcitabine + carboplatin; Pemetrexed + cisplatin; Pemetrexed + carboplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2015-11-03
    Completion
    2026-12-31
    Enrolment
    953

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon Small Cell Lung Carcinoma NSCLC
    InterventionDurvalumab +Tremelimumab; Paclitaxel + carboplatin; Gemcitabine + cisplatin; Gemcitabine + carboplatin +2 more
    PhasePhase 3
    Registry statusActive not recruiting

  • Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma

    NCT02399566 · start 2015-05

    Registered record
    Registry ID
    NCT02399566
    Conditions
    Lung Adenocarcinoma
    Interventions
    Erlotinib, Pemetrexed
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2015-05
    Completion
    2019-01
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Adenocarcinoma
    InterventionErlotinib, Pemetrexed
    PhasePhase 4
    Registry statusUnknown

  • Sym004 in Subjects With Stage IV Non-small Cell Lung Cancer

    NCT02083679 · start 2014-07

    Registered record
    Registry ID
    NCT02083679
    Conditions
    Carcinoma, Non-Small-Cell Lung
    Interventions
    Part 1: Sym004 6 mg/kg + Cisplatin/Gemcitabine; Part 1: Sym004 6 mg/kg + Cisplatin/Pemetrexed; Part 1: Sym004 6 mg/kg + Carboplatin/Paclitaxel; Part 1: Sym004 6/12 mg/kg + Carboplatin/Paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2014-07
    Completion
    2015-08
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Non-Small-Cell Lung
    InterventionPart 1: Sym004 6 mg/kg + Cisplatin/Gemcitabine; Part 1: Sym004 6 mg/kg + Cisplatin/Pemetrexed; Part 1: Sym004 6 mg/kg + Carboplatin/Paclitaxel; Part 1: Sym004 6/12 mg/kg + Carboplatin/Paclitaxel
    PhasePhase 1
    Registry statusTerminated

  • Phase I Study of Tetrathiomolybdate in Combination With Carboplatin/Pemetrexed in Metastatic Non-small Cell Lung Cancer

    NCT01837329 · start 2013-11

    Registered record
    Registry ID
    NCT01837329
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    Tetrathiomolybdate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-11
    Completion
    2019-01-11
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    InterventionTetrathiomolybdate
    PhasePhase 1
    Registry statusCompleted

  • Neoadjuvant Chemo for Non-metastatic Non-small Cell Lung Cancer

    NCT01860040 · start 2013-04

    Registered record
    Registry ID
    NCT01860040
    Conditions
    Non-squamous Cell Non-Metastatic Non-Small Cell Lung Cancer; Squamous Cell Non-Metastatic Non-Small Cell Lung Cancer
    Interventions
    Cisplatin; Pemetrexed; Gemcitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2013-04
    Completion
    2016-04
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-squamous Cell Non-Metastatic Non-Small Cell Lung Cancer; Squamous Cell Non-Metastatic Non-Small Cell Lung Cancer
    InterventionCisplatin; Pemetrexed; Gemcitabine
    PhasePhase 2
    Registry statusTerminated

  • Genius Study Study to Compare Efficacy and Safety of Gefitinib/ Pemetrexed With Pemetrexed Alone as Maintenance Therapy in Patients With Stage IV EGFR Mutation Negative or T790M Single Mutation Who Respond to Pemetrexed/ Platinum as First-line Therapy

    NCT01579630 · start 2011-03

    Registered record
    Registry ID
    NCT01579630
    Conditions
    NSCLC
    Interventions
    Pemetrexed 500mg/m2 iv; Pemetrexed 500mg/m2 iv and Gefitinib 250 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2011-03
    Completion
    2014-06
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNSCLC
    InterventionPemetrexed 500mg/m2 iv; Pemetrexed 500mg/m2 iv and Gefitinib 250 mg
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial).

    NCT01116219 · start 2010-06

    Registered record
    Registry ID
    NCT01116219
    Conditions
    Lung Cancer
    Interventions
    bevacizumab, erlotinib; bevacizumab, pemetrexed, cisplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-06
    Completion
    2016-05
    Enrolment
    149

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer
    Interventionbevacizumab, erlotinib; bevacizumab, pemetrexed, cisplatin
    PhasePhase 2
    Registry statusCompleted

  • Response Evaluation in Malignant Pleural Mesothelioma

    NCT00969098 · start 2009-06

    Registered record
    Registry ID
    NCT00969098
    Conditions
    Malignant Pleural Mesothelioma
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2009-06
    Completion
    2015-09
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalignant Pleural Mesothelioma
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • Personalized Therapy in Non-small Cell Lung Cancer

    NCT01781988 · start 2009-06

    Registered record
    Registry ID
    NCT01781988
    Conditions
    Lung Cancer; Carboplatin Adverse Reaction
    Interventions
    carboplatin, gemcitabine , pametrexed
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-06
    Completion
    2014-12
    Enrolment
    128

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer; Carboplatin Adverse Reaction
    Interventioncarboplatin, gemcitabine , pametrexed
    PhasePhase 2
    Registry statusCompleted